RecruitingNarcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Eligible age

18–65 yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

Sponsor: Centessa Pharmaceuticals (UK) Limited

You may qualify if…

✓ Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
✓ Is willing and able to adhere to additional protocol requirements

You may not qualify if…

✕ Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study
✕ Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia